Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Is INmune Bio’s Breakthrough Turning Heads?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 6/27/2025, 9:18 am ET 6 min read
Is INmune Bio’s Breakthrough Turning Heads? Thumbnail

INmune Bio Inc. stocks have been trading up by 54.93% following positive sentiment around FDA designation announcements.

News Surrounding Market Shifts

  • Promising preclinical study results for XPro by INmune Bio, Inc. might indicate an early triumph in Alzheimer’s treatment following traumatic brain injuries. The Department of Defense-backed findings highlight amyloid reduction and improved clinical measures.
  • Anticipation builds as INmune Bio Inc. prepares to unveil significant results from phase 2 trials of their Alzheimer’s treatment, XPro™, aiming at early disease management.
  • With groundbreaking steps in Alzheimer’s research, INMB is positioned as a potential frontrunner, capturing the attention of both investors and healthcare professionals.

Candlestick Chart

Live Update At 09:18:01 EST: On Friday, June 27, 2025 INmune Bio Inc. stock [NASDAQ: INMB] is trending up by 54.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of INmune Bio Inc.’s Financial Health

“Cut losses quickly, let profits ride, and don’t overtrade.” As millionaire penny stock trader and teacher Tim Sykes says, these are essential principles for traders to follow. Proper adherence to these guidelines ensures that traders can navigate the volatile markets effectively. In the world of trading, understanding risk management is crucial; knowing when to exit a losing trade and allowing winning trades to meet their full potential can significantly impact overall success. Additionally, by avoiding overtrading, traders can maintain a clear and focused strategy without succumbing to emotional decision-making. Traders who keep these principles in mind are better positioned for long-term success.

INmune Bio Inc.’s journey, shrouded in scientific triumphs and financial challenges, paints a vivid picture. The company has seen revenue dipping by nearly half over three years, standing at a valuation seemingly hefty with a price-to-sales ratio exceeding 3,400. While debt appears minimal, liquidity remains delicate with a current ratio of 2.6, maintaining enough to handle short-term obligations. Shareholders might raise eyebrows at the company’s negative returns on assets and equity, hinting at underutilized resources amidst aggressive spending.

More Breaking News

Recent financial reports reflected a loss with net incomes adding up to a noticeable minus, alongside operating cash flows following suit. Yet, optimism gleams brightly as research ventures emerge, underpinned by external funding and significant capital stock raises. The surge in interest, stoked by INmune’s promising Alzheimer’s drug initiatives, ignites investor curiosity.

Preclinical Revelations: A Turning Point for INmune Bio?

INmune Bio, Inc. recently unveiled triumphs within their preclinical studies for XPro, marking a pivotal moment in their journey to combat Alzheimer’s Disease post-traumatic brain injury. Supported by the Department of Defense, these studies spotlight XPro’s efficacy in reducing amyloid build-up, a significant obstacle in Alzheimer’s. Early findings indicating improved neurological outcomes present a beacon of hope in the quest for an effective treatment. The potential breakthrough has investors on edge, spurring interest in future developments.

With such promising results, speculation around XPro’s influence not only holds a scientific allure but translates into potential financial gains for INmune Bio. Their entry price sways with each new finding, and the current landscape may present a strategic point for potential investors to evaluate current and long-term benefits. Still, these developments reflect only an early chapter in what could be a monumental health solution journey.

Phase 2 Trials: A Leap for INmune Bio

As INmune Bio prepares to reveal results from its phase 2 trial for XPro™, the air of anticipation is palpable. With the focus on early Alzheimer’s disease management, positive results could cement their reputation as pioneers in this realm. The XPro drug aims for neural protection, thus, its impact on Alzheimer’s-related markers during trials could pivot the company into a new league.

This momentum showcases INmune Bio’s promise to both investors and pharmaceutical communities, potentially elevating the market value of its shares. However, the path remains paved with challenges as trial outcomes could swing markets in unimaginable directions. Stakeholders eagerly anticipate these results with the hope they reflect the positive trajectory demonstrated in prior data.

Financial and Market Position: What Lies Ahead

Reflecting on INmune Bio’s recent earnings, one cannot ignore the juxtaposition between potential scientific breakthroughs and lingering financial deficits. The company showcases a breadth of research endeavors while navigating tight financial currents. Each strategic scientific milestone enhances their market narrative, albeit against a backdrop of fiscal caution, where elusive profitability remains a challenge.

Watching INmune Bio tread through this financial labyrinth is no less gripping than a suspense novel, with the promise of scientific success teasing at the narrative’s conclusion. The journey of stock prices undoubtedly hinges not just on flash news pieces but on constructing enduring financial stability with each promising study and milestone achieved.

Summary: INmune Bio’s Position Amidst Market Waves

The recent revelations from INmune Bio Inc. lay the groundwork for a compelling narrative. From promising Alzheimer’s treatment developments to speculative clinical results, each revelation has the potential to shift the stock market’s gaze and bolster their standing. For traders and onlookers keen on therapeutic advancements, these scientific victories translate into speculative queries around financial fortune. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This mindset should guide those engaging with INmune Bio’s fluctuating market presence. The coming chapters in INmune Bio’s tale promise not just to captivate but also redefine its role as a potential leader in the pharmaceutical sector. Discerning eyes will need to weigh both the current financial puzzle and burgeoning scientific horizons to foresee the next act in INMB’s evolving saga.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications